{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:40:38Z","timestamp":1787755238556,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40123-026-01462-6","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:59:58Z","timestamp":1785175198000},"page":"3089-3100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Photodynamic Therapy in Central Serous Chorioretinopathy: Treatment Timing, Anatomical Response, and Recurrence in a Large Real-World Cohort"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3820-6552","authenticated-orcid":false,"given":"Caroline M.","family":"St\u00fcven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Klaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Siedlecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried G.","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie F.","family":"Keidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schworm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"9","key":"1462_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00347-021-01376-7","volume":"118","author":"L Pauleikhoff","year":"2021","unstructured":"Pauleikhoff L, Agostini H, Lange C. Central serous chorioretinopathy. Ophthalmologe. 2021;118(9):967\u201380.","journal-title":"Ophthalmologe"},{"key":"1462_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100865","volume":"79","author":"R Kaye","year":"2020","unstructured":"Kaye R, Chandra S, Sheth J, Boon CJF, Sivaprasad S, Lotery A. Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res. 2020;79:100865.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1462_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00417-019-04486-w","volume":"258","author":"G Ge","year":"2020","unstructured":"Ge G, Zhang Y, Zhang Y, Xu Z, Zhang M. Corticosteroids usage and central serous chorioretinopathy: a meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2020;258(1):71\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1462_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82\u2013118.","journal-title":"Prog Retin Eye Res"},{"issue":"9","key":"1462_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm12093102","volume":"12","author":"LF Keidel","year":"2023","unstructured":"Keidel LF, Schworm B, Langer J, Luft N, Herold T, Hagenau F, et al. Scleral thickness as a risk factor for central serous chorioretinopathy and pachychoroid neovasculopathy. J Clin Med. 2023;12(9):1.","journal-title":"J Clin Med"},{"issue":"12","key":"1462_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.oret.2019.08.002","volume":"3","author":"J Siedlecki","year":"2019","unstructured":"Siedlecki J, Schworm B, Priglinger SG. The pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina. 2019;3(12):1013\u20135.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"1462_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/IAE.0b013e318218a95a","volume":"32","author":"TL Jackson","year":"2012","unstructured":"Jackson TL, Hussain A, Salisbury J, Sherwood R, Sullivan PM, Marshall J. Transscleral albumin diffusion and suprachoroidal albumin concentration in uveal effusion syndrome. Retina. 2012;32(1):177\u201382.","journal-title":"Retina"},{"issue":"5","key":"1462_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10384-024-01101-2","volume":"68","author":"H Koizumi","year":"2024","unstructured":"Koizumi H, Imanaga N, Terao N. Central serous chorioretinopathy and the sclera: what we have learned so far. Jpn J Ophthalmol. 2024;68(5):419\u201328.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"1462_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0161-6420(99)00141-4","volume":"107","author":"M Uyama","year":"2000","unstructured":"Uyama M, Takahashi K, Kozaki J, Tagami N, Takada Y, Ohkuma H, et al. Uveal effusion syndrome: clinical features, surgical treatment, histologic examination of the sclera, and pathophysiology. Ophthalmology. 2000;107(3):441\u20139.","journal-title":"Ophthalmology"},{"issue":"1","key":"1462_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40942-023-00443-2","volume":"9","author":"A Zarnegar","year":"2023","unstructured":"Zarnegar A, Ong J, Matsyaraja T, Arora S, Chhablani J. Pathomechanisms in central serous chorioretinopathy: a recent update. Int J Retina Vitreous. 2023;9(1):3.","journal-title":"Int J Retina Vitreous"},{"issue":"2","key":"1462_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000360014","volume":"232","author":"R Liegl","year":"2014","unstructured":"Liegl R, Ulbig MW. Central serous chorioretinopathy. Ophthalmol. 2014;232(2):65\u201376.","journal-title":"Ophthalmol"},{"issue":"10","key":"1462_CR12","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125(10):1547\u201355.","journal-title":"Ophthalmology"},{"key":"1462_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","volume":"233","author":"TJ van Rijssen","year":"2022","unstructured":"van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, et al. Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial. Am J Ophthalmol. 2022;233:101\u201310.","journal-title":"Am J Ophthalmol"},{"key":"1462_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101236","volume":"101","author":"HMA Feenstra","year":"2024","unstructured":"Feenstra HMA, van Dijk EHC, Cheung CMG, Ohno-Matsui K, Lai TYY, Koizumi H, et al. Central serous chorioretinopathy: an evidence-based treatment guideline. Prog Retin Eye Res. 2024;101:101236.","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"1462_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jfo.2023.02.003","volume":"46","author":"E Bousquet","year":"2023","unstructured":"Bousquet E, Provost J, Torres-Villaros H, Behar-Cohen F. Central serous chorioretinopathy: a review. J Fr Ophtalmol. 2023;46(7):791\u2013802.","journal-title":"J Fr Ophtalmol"},{"key":"1462_CR16","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","volume":"106","author":"S Kwiatkowski","year":"2018","unstructured":"Kwiatkowski S, Knap B, Przystupski D, Saczko J, K\u0119dzierska E, Knap-Czop K, et al. Photodynamic therapy\u2014mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098\u2013107.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1462_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1146\/annurev-vision-102122-102907","volume":"10","author":"AH Khan","year":"2024","unstructured":"Khan AH, Lotery AJ. Central serous chorioretinopathy: epidemiology, genetics and clinical features. Annu Rev Vis Sci. 2024;10(1):477\u2013505.","journal-title":"Annu Rev Vis Sci"},{"key":"1462_CR18","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-031-72230-1_53","volume":"1467","author":"JK Oh","year":"2025","unstructured":"Oh JK, Diaconita V, Tezel TH. Central serous chorioretinopathy. Adv Exp Med Biol. 2025;1467:277\u201380.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"1462_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"1980","unstructured":"Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980\u20132002. Ophthalmology. 1980;115(1):169\u201373.","journal-title":"Ophthalmology"},{"issue":"10","key":"1462_CR20","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s40123-025-01220-0","volume":"14","author":"IN Frederiksen","year":"2025","unstructured":"Frederiksen IN, Arnold-Vangsted A, Anguita R, Boberg-Ans LC, Cehofski LJ, van Dijk EHC, et al. Global incidence of central serous chorioretinopathy: a systematic review, meta-analysis, and forecasting study. Ophthalmol Ther. 2025;14(10):2443\u201367.","journal-title":"Ophthalmol Ther"},{"issue":"5","key":"1462_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0039-6257(02)00338-7","volume":"47","author":"EA Bouzas","year":"2002","unstructured":"Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431\u201348.","journal-title":"Surv Ophthalmol"},{"key":"1462_CR22","first-page":"799","volume":"84","author":"LA Yannuzzi","year":"1986","unstructured":"Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799\u2013845.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"3","key":"1462_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ceo.14201","volume":"51","author":"AT Fung","year":"2023","unstructured":"Fung AT, Yang Y, Kam AW. Central serous chorioretinopathy: a review. Clin Exp Ophthalmol. 2023;51(3):243\u201370.","journal-title":"Clin Exp Ophthalmol"},{"issue":"11","key":"1462_CR24","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/bjophthalmol-2021-318953","volume":"106","author":"ZJ Chen","year":"2022","unstructured":"Chen ZJ, Lu SY, Rong SS, Ho M, Ng DS, Chen H, et al. Genetic associations of central serous chorioretinopathy: a systematic review and meta-analysis. Br J Ophthalmol. 2022;106(11):1542\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1462_CR25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4103\/0974-9233.97920","volume":"19","author":"K Said-Ahmed","year":"2012","unstructured":"Said-Ahmed K, Moustafa G, Fawzy M. Incidence and natural course of symptomatic central serous chorioretinopathy in pregnant women in a maternity hospital in Kuwait. Middle East Afr J Ophthalmol. 2012;19(3):273\u20136.","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"3","key":"1462_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.mehy.2004.02.020","volume":"63","author":"C Giusti","year":"2004","unstructured":"Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Med Hypotheses. 2004;63(3):524\u20137.","journal-title":"Med Hypotheses"},{"issue":"3","key":"1462_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ophtha.2024.09.003","volume":"132","author":"LA Kim","year":"2025","unstructured":"Kim LA, Maguire MG, Weng CY, Smith JR, Jain N, Flaxel CJ, et al. Therapies for central serous chorioretinopathy: a report by the American Academy of Ophthalmology. Ophthalmology. 2025;132(3):343\u201353.","journal-title":"Ophthalmology"},{"key":"1462_CR28","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","volume":"73","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen TJ, van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770.","journal-title":"Prog Retin Eye Res"},{"key":"1462_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2019.03.025","volume":"205","author":"TJ van Rijssen","year":"2019","unstructured":"van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report no. 3. Am J Ophthalmol. 2019;205:1\u201310.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1462_CR30","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/aos.14775","volume":"99","author":"TJ van Rijssen","year":"2021","unstructured":"van Rijssen TJ, van Dijk EHC, Scholz P, Breukink MB, Dijkman G, Peters PJH, et al. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. Acta Ophthalmol. 2021;99(7):805\u201311.","journal-title":"Acta Ophthalmol"},{"key":"1462_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ajo.2024.11.014","volume":"271","author":"M Zaman","year":"2025","unstructured":"Zaman M, Mihalache A, Huang RS, Shah N, Popovic MM, Kertes PJ, et al. Safety and efficacy of half-dose and half-fluence photodynamic therapy in chronic central serous chorioretinopathy: a systematic review and meta-analysis. Am J Ophthalmol. 2025;271:233\u201342.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1462_CR32","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/aos.17507","volume":"103","author":"JM Chang-Wolf","year":"2025","unstructured":"Chang-Wolf JM, van Dijk EHC, El Boujdaini K, van Straaten M, van Rijssen TJ, Schlingemann RO, et al. Outcome and safety of multiple photodynamic therapy sessions in chronic central serous chorioretinopathy. Acta Ophthalmol. 2025;103(7):782\u201390.","journal-title":"Acta Ophthalmol"},{"key":"1462_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15010043","author":"M Latalska","year":"2025","unstructured":"Latalska M, Dresler S, W\u00f3jciak M, Sowa I, Rejdak R. A novel panmacular strategy for subthreshold micropulse laser in CSC: two-year functional and morphological outcomes. J Clin Med. 2025. https:\/\/doi.org\/10.3390\/jcm15010043.","journal-title":"J Clin Med"},{"issue":"4","key":"1462_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/bjophthalmol-2020-316076","volume":"105","author":"M Ho","year":"2021","unstructured":"Ho M, Lai FHP, Ng DSC, Iu LPL, Chen LJ, Mak ACY, et al. Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol. 2021;105(4):555\u201360.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1462_CR35","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s40123-024-00952-9","volume":"13","author":"MJ Sirks","year":"2024","unstructured":"Sirks MJ, Subhi Y, Rosenberg N, Hollak CEM, Boon CJF, Diederen RMH, et al. Perspectives and update on the global shortage of verteporfin (Visudyne(\u00ae)). Ophthalmol Ther. 2024;13(7):1821\u201331.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1462_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0161-6420(96)30730-6","volume":"103","author":"DA Quillen","year":"1996","unstructured":"Quillen DA, Gass DM, Brod RD, Gardner TW, Blankenship GW, Gottlieb JL. Central serous chorioretinopathy in women. Ophthalmology. 1996;103(1):72\u20139.","journal-title":"Ophthalmology"},{"key":"1462_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061706","author":"E Bousquet","year":"2022","unstructured":"Bousquet E, Torres-Villaros H, Provost J, Elalouf M, Gigon A, Mantel I, et al. Clinical characteristics and multimodal imaging findings of central serous chorioretinopathy in women versus men. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11061706.","journal-title":"J Clin Med"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01462-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01462-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01462-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:39:51Z","timestamp":1787751591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01462-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01462-6","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors\u2019 financial interests are directly or indirectly related to this work. Caroline M. St\u00fcven has no financial disclosure to declare. Benedikt Schworm has received previous speaker fees of Novartis Pharma, Bayer Vital, Amgen. Tina Herold received previous Honoraria of Novartis, Bayer Healthcare, Abbvie, Roche, Novonordisk and travel expenses of Roche. Julian Klaas has received previous speaker fees and Advisory Honoraria for Novartis und Roche. Jakob Siedlecki is part of the advisory board and got honoraria of Novaris Pharma, Abbvie\/Pharm-Allergan, Roche, Apellis, Sandoz\/Hexal and he is part of the advisory board of Bayer. Paul Foerster has no financial disclosure to declare. Siegfried G. Priglinger is part of the advisory board and received previous honoraria of Novartis Pharma, Pharm Allergan, Zeiss, Bayer, Bausch and Lomb, Roche, AbbVie, he is a Consulant of BVI Medical, Bausch and Lomb, Roche and AbbVie. Leonie F. Keidel received previous speaker fees and\/or travel expenses from Novartis Pharma, Recordati Rare Diseases Inc., CHIESI, Roche Diagnostics, DORC Holding BV and Santen.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the tenets of the Declaration of Helsinki and was classified as ethically and legally unobjectionable by the ethics committee of the LMU Munich (identifier: 25-0363). This retrospective study was conducted using anonymized patient data, and therefore, the requirement for informed consent was waived by the local ethics committee in accordance with applicable regulations.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We thank the participants of the study.","order":3,"name":"Ethics","label":"Thanking Patients","group":{"name":"EthicsHeading","label":"Declarations"}}]}}